×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
NASDAQ:ATNF

180 Life Sciences Stock Forecast, Price & News

$0.91
+0.04 (+4.60%)
(As of 07/5/2022 03:50 PM ET)
Add
Compare
Today's Range
$0.85
$0.91
50-Day Range
$0.81
$2.13
52-Week Range
$0.79
$11.20
Volume
981 shs
Average Volume
306,110 shs
Market Capitalization
$31.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

180 Life Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,122.2% Upside
$11.00 Price Target
Short Interest
Healthy
3.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.71 out of 5 stars

Medical Sector

837th out of 1,428 stocks

Pharmaceutical Preparations Industry

418th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ATNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

180 Life Sciences logo

About 180 Life Sciences (NASDAQ:ATNF) Stock

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

ATNF Stock News Headlines

The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
180 Life Sciences Corp. (ATNF)
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
180 Life Sciences Corp. Forms Scientific Advisory Board
180 Life Sciences Corp. Expands Patent Portfolio
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATNF
Fax
N/A
Employees
2
Year Founded
N/A

Company Calendar

Last Earnings
5/16/2022
Today
7/05/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+1,108.8%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
1 Analysts

Profitability

Net Income
$-20,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.16 per share

Miscellaneous

Free Float
28,954,000
Market Cap
$31.07 million
Optionable
Not Optionable
Beta
0.18














180 Life Sciences Frequently Asked Questions

Should I buy or sell 180 Life Sciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 180 Life Sciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" 180 Life Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNF, but not buy additional shares or sell existing shares.
View analyst ratings for 180 Life Sciences
or view top-rated stocks.

What is 180 Life Sciences' stock price forecast for 2022?

1 brokers have issued 1-year price targets for 180 Life Sciences' stock. Their ATNF stock forecasts range from $11.00 to $11.00. On average, they expect 180 Life Sciences' stock price to reach $11.00 in the next year. This suggests a possible upside of 1,108.8% from the stock's current price.
View analysts' price targets for 180 Life Sciences
or view top-rated stocks among Wall Street analysts.

How has 180 Life Sciences' stock price performed in 2022?

180 Life Sciences' stock was trading at $3.90 at the start of the year. Since then, ATNF stock has decreased by 76.7% and is now trading at $0.91.
View the best growth stocks for 2022 here
.

When is 180 Life Sciences' next earnings date?

180 Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for 180 Life Sciences
.

How were 180 Life Sciences' earnings last quarter?

180 Life Sciences Corp. (NASDAQ:ATNF) issued its quarterly earnings data on Monday, May, 16th. The company reported ($0.05) earnings per share for the quarter.
View 180 Life Sciences' earnings history
.

Who are 180 Life Sciences' key executives?

180 Life Sciences' management team includes the following people:
  • Dr. James N. Woody M.D., Ph.D., CEO & Director (Age 80, Pay $448.27k)
  • Mr. Ozan Pamir C.F.A., Interim CFO & Sec. (Age 30, Pay $334.36k) (LinkedIn Profile)
  • Mr. Quan Anh Vu, COO & Chief Bus. Officer (Age 50, Pay $372k)
  • Dr. Jonathan B. Rothbard Ph.D., Chief Scientific Officer (Age 70, Pay $372.03k)
  • Dr. Raphael Mechoulam Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Mr. Jason Assad, Director of IR
  • Prof. Jagdeep Nanchahal, Chief Medical Officer & Chairman of Clinical Advisory Board

What is 180 Life Sciences' stock symbol?

180 Life Sciences trades on the NASDAQ under the ticker symbol "ATNF."

How do I buy shares of 180 Life Sciences?

Shares of ATNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 180 Life Sciences' stock price today?

One share of ATNF stock can currently be purchased for approximately $0.91.

How much money does 180 Life Sciences make?

180 Life Sciences (NASDAQ:ATNF) has a market capitalization of $31.07 million.

How many employees does 180 Life Sciences have?

180 Life Sciences employs 2 workers across the globe.

How can I contact 180 Life Sciences?

180 Life Sciences' mailing address is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. The official website for 180 Life Sciences is www.kblmerger.com. The company can be reached via phone at (650) 507-0669 or via email at jason@180lifesciences.com.

This page (NASDAQ:ATNF) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.